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Purpose: Directional atherectomy is an endovascular interventional technique for excision 
and removal of obstructive arterial esions. To evaluate whether atherectomy would 
provide better results than conventional balloon angioplasty (BA) in symptomatic 
femoropopliteal disease, a prospective randomized study comparing the early and late 
outcomes of these techniques was conducted. The rate of restenosis or occlusion was 
assessed by use of color-flow duplex scanning during the follow-up period. 
Methods: Seventy-three patients were randomized between athereetomy (38 patients) and 
BA (35 patients). All patients had segmental lesions of the femoropopliteal rteries 
amenable to either technique. The median follow-up duration was 13 months (range i to 
39)° Follow-up comprised regular clinical and hemodynamic assessment and color-flow 
duplex examinations. Restenosis was defined on the basis of a peak systolic velocity ratio 
of 2.5 or greater, and occlusion of the treated segment was diagnosed if flow signals were 
absent, that is, loss of patency. 
Results: Residual stenoses (-> 30% diameter reduction) resulted in five patients (13%) 
undergoing atherectomy and three patients (9%) undergoing BA. At I month clinical and 
hemodynamic improvement by Society for Vascular Surgery/International Society for 
Cardiovascular Surgery criteria for lower limb ischemia was observed in 34 patients (89%) 
treated with atherectomy and in 34 (97%) treated with BA. By life-table analysis the 
cumulative rate of clinical and hemodynamic su cess at 2 years was 52% in patients treated 
with atherectomy and 87% in patients treated with BA (p = 0.06). The patency rate at 2 
years of treated segments was 34% in the atherectomy group and 56% in patients treated 
with BA (p = 0.07). In patients with lesions greater than 2 cm, the 1-year patency rate of 
AT was significantly ower than BA (p = 0.03). 
Conclusions: Atherectomy does not result in an improved clinical and hemodynamic 
outcome. Furthermore atherectomy of segmental therosclerotic femoropopliteal disease 
does not result in a better patency rate than BA, and, in lesions with greater length than 
2 cm, the atherectomy results are significantly worse. (J VAsc SURG 1995;21:255-69.) 
Directional atherectomy was developed to reduce 
the relatively high incidence of late restenosis after 
conventional balloon angioplasty (BA) for peripheral 
arterial occlusive disease in medium- and small-sized 
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arteries like the femoropopliteal vessels. ~'2 Dissec- 
tions, cracks from disrupted plaque material, often 
occur after balloon dilation of a lesion. The healing 
process of traumatized vessel wall may result in 
myointimal hyperplasia, whereas residual intima] 
flaps and thrombus may contribute to this process as 
well. In addition, elastic recoil of the overstretched 
vessel wall may be associated with an early loss of 
postprocedural luminal diameter? In atherectomy 
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the atherosclerotic tissue is removed by excision, 
providing a more aesthetic vessel wall that is per- 
haps less susceptible for subsequent proliferation of 
smooth muscle cells. Although many procedures 
have been performed in peripheral arteries and 
satisfactory initial results with low complication rates 
were documented, a controlled comparison of the 
late results ofatherectomy with those obtained by BA 
has not been performed. 1,2,4,s Furthermore, assess- 
ment of results at follow-up often was based on 
clinical and indirect hemodynamic parameters rather 
than on anatomic information obtained by arteriog- 
raphy or duplex examination, s,6
The purpose of this study was to evaluate whether 
atherectomy would provide advantages over conven- 
tional BA in the treatment of appropriate occlusive 
lesions in the femoropopliteal rteries. Therefore a
prospective randomized study was undertaken to 
compare arly and late outcome of these two methods 
for endovascular treatment. In addition to clinical 
and hemodynamic assessment, anatomic hanges in 
the involved femoropopliteal rteries were moni- 
tored by serial color-flow duplex examinations. Ana- 
tomic failure (loss ofpatency) was indicated either by 
increased flow velocities in restenoses or absence of 
flow in occluded arterial segments. The influence of 
several clinical and morphologic baseline factors on 
the combined endpoint of late restenosis and occlu- 
sion was studied. 
PATIENTS AND METHODS 
Seventy-three patients with femoropopliteal ob- 
structive lesions were recruited from January 1990 
until May 1993. Only one limb per patient was stud- 
ied. Eligible patients included those with intermittent 
claudication of at least 3 months duration and ob- 
structive lesions of the femoropopliteal arteries that 
appeared suitable for either atherectomy or balloon 
angioplasty (BA), that is, lesions with a maximum 
length of 5 cm. This restriction was because atherec- 
tomy is only applicable in discrete stenoses or short 
occlusions. Therefore any patient with a diffusely dis- 
eased femoropopliteal artery with a stenosis extend- 
ing more than 5 cm or an occlusion longer than 2 cm 
was not considered a good candidate for the trial and 
was relegated to an obligatory balloon dilation. Only 
de novo lesions were admitted, and any previous 
ipsilateral femoropopliteal endovascular o operative 
intervention was considered an exclusion criterion, 
irrespective ofwhether this treatment had concerned 
a different segment from the one considered for inter- 
vention at the time of the study. Only patients were 
selected who would be able to comply with the 
frequent follow-up visits required by the involved 
color-flow duplex surveillance protocol. Preopera- 
five assessment included measurement of Doppler 
ankle-brachial blood pressure index (ABI) and 
aortography/arteriography with use of intraarterial 
digital subtraction angiography for the evaluation of 
the femoropopliteal and crural segments. The degree 
of stenosis was calculated on the basis of a reduction 
of the diameter at the narrowest part of the stenosis 
compared with a nearby ~'normal" arterial segment. 
The length of observed stenoses was measured on the 
pretreatment ar eriography. 
Prospective subjects for the trial were identified 
after their eligibility for the study was confirmed, and 
randomization occurred only when the vascular 
surgeon and the radiologist had established that the 
recruitment criteria were satisfied. Patients gave 
consent according to the standards of the institu- 
tional Ethical Review Committee. Among patients 
who were clinically and arteriographically e igible for 
the study, four patients were excluded for logistic 
reasons, and one patient declined to be randomized. 
The 73 endovascular p ocedures comprised 39% of 
all balloon angioplasty and atherectomy procedures 
in the femoropopliteal arteries performed during the 
trial period. 
Technique for endovascular p ocedures 
A standard technique of BA as has been described 
previously by others was used in this study. 7The 
directional atherectomy device consists of a hollow 
cutting cylinder with a window on one side and a 
balloon on the opposite side. Inflation of the balloon 
pushes the window against the diseased arterial wall, 
and obstructing plaque protrudes into the cylinder. A
high-speed rotating cutter shaves off the plaque and 
pushes it into a collection chamber. The atherectomy 
procedure was carried out according to the guidelines 
of Schwarten et al. ~ and Fogarty et al.8 These can be 
summarized as follows. An introducer sheath is 
advanced in an antegrade fashion through an arterial 
puncture in the common femoral artery either 
percutaneously (in the angiography suite) or via a 
"cutdown" approach (in the operating room). The 
patient receives 5000 IU of heparin intraarterially, 
and, under fluoroscopic guidance, a 6F to 8F 
atherectomy catheter (Simpson Atherocath; De- 
vices for Vascular Intervention, Inc., Redwood City, 
Calif.) is advanced istally. The size of the atherec- 
tomy catheter was chosen so that the working 
diameter, with the balloon inflated, was equal to 
slightly greater than a normal adjacent artery seg- 
ment. The opening in the cylindrical housing is 
turned toward the stenosis ite, and the balloon is 
inflated to 10 psi. The tubular blade is then retracted 
proximally, and the balloon pressure is increased to 
30 psi. The rotatory knife (2000 rpm) is driven by a 
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battery-powered motor, and a section of the plaque 
is shaved off and stored within the cylindrical 
housing. Multiple passes with the rotatory lmife are 
made. After a cut is made, the balloon is deflated, and 
the catheter is rotated. The balloon is then again 
reinflated, and more of the plaque is removed. The 
catheter is rotated several times to obtain a series of 
overlapping excisions. During the procedure the 
collection chamber has to be emptied several times, 
and the process is repeated until a satisfactory 
angiographic result is obtained. All patients began 
receiving 80 mg aspirin orally the day before the 
endovascular intervention was performed, and ad- 
ministration of aspirin was continued indefinitely. 
Endovascnlar procedures were performed by a mul- 
tidisciplinary team of radiologists and vascular sur- 
geons, either in the catheterization laboratory or 
operating room. Use of only the technique selected 
by randomization was attempted, although crossover 
was permitted if an acceptable result could only be 
obtained by the opposite technique or by combined 
techniques. Second and third obstructive l sions were 
invariably treated by the technique used for the index 
lesion. 
Follow-up methods 
The follow-up protocol included clinical investi- 
gations by anlde pressure measurements with the 
patient at rest and after graded treadmill exercise and 
color-flow duplex examinations every 3 months after 
the procedure during the first year and every 6 
months during the second year. Color-flow duplex 
scanning consisted of obtaining an image of the 
entire femoropopliteal segment from the groin to the 
popliteal trifurcation. The diameter of the superficial 
femoral artery.. (SFA) at a proximal normal segment 
was measured (in tenths of millimeters). Occlusions 
were characterized by the absence of detectable flow 
in the main artery and increased collateral flow. 
Stenotic segments were identified by locally increased 
velocities and poststenotic turbulence characterized 
by color-coded changes. Doppler velocity signals 
were recorded from normal and any diseased seg- 
ments. Preintervention arteriograms were used to 
enable differentiation between restenosis and new 
stenoses. A ruler was used to determine the precise 
location of abnormal f ow sites in relation to the knee 
joint. Stenotic lesions identified by color-flow duplex 
scanning were drawn on a diagram of the femo- 
ropopliteal arteries, with the SFA divided into four 
segments (designated from proximally S1, $2, $3, $4) 
and the popliteal artery into an above-lmee and 
below-knee segment (designated Pl and P2)" These 
six segments allowed recognition of specific lesions at 
different examinations. The peak systolic velocity at 
the site of the stenosis (PSV stenosis) was compared 
with the PSV of a nearby normal arterial segment 
(PSV artery) and the PSV ratio was calculated (PSV 
ratio = PSV stenosis/PSV artery). Our institutional 
accuracy of grading stenosis in femoropopliteal r.. 
teries was validated by prospectively comparing PSV 
ratios, by use of a criterion of greater than 2.5 for 
hemodynamically important lesions, with the appro- 
priate arteriograms in 132 consecutive patients. The 
observed sensitivity of identifying significant stenoses 
was 84% (67/80), and the specificity was 100% 
(52/52). 
Definitions, study endpoints, and data analysis 
All data were prospectively recorded and entered 
into a computerized database. The endovascular in- 
terventions were evaluated for immediate technical 
success and early and late clinical and hemodynamic 
success. Technical success was defined as a residual 
stenosis of less than 30% diameter eduction on 
completion arteriography. Clinical and hemody- 
namic outcome was classified according to Society 
for Vascular Surgery/International Society fbr Car- 
diovascular Surgery criteria on a scale from - 1 to 
-3  for deterioration of symptoms and ABI, 0 ~br 
unchanged symptoms, + 1 for either a categorical 
improvement of clinical classification of daudication 
or increase of ABI greater than 0.10, +2 for at least 
a single category improvement of claudication com- 
bined with ABI increase of greater than 0.10, and + 3 
for markedly improved symptoms combined with an 
ABI > 0.90. 9 
Late anatomic success or patency was determined 
by color-flow duplex surveillance. As a baseline char- 
acteristic the severest lesion is considered the index 
lesion. All lesions that recurred during follow-up 
within be  same arterial segment are considered reste- 
noses. Lesions in different segments hat are treated at 
the same time are associate l sions, and their recur- 
rences also are defined as restenoses. The severest of 
the restenoses i  the lesion whose velocity values are 
used for the patency analysis. When studied as a di- 
chotomous variable, aPSV ratio greater than 2.5 was 
the criterion for resrenosis. Progression of disease in 
nontreated arterial segments is defined new lesions. 
These lesions are not considered for the analysis of 
late patency. 
PSV ratios of treated arterial segments were 
analyzed in two different ways. In cumulative fre- 
quency distribution curves, the PSV ratio is ap- 
proached as a continuous variable directly represent- 
ing the magnitude of the diameter reduction. In this 
graphic technique complete series of data are visual- 
ized without the loss of information inherent o a 
dichotomous approach. 1°,11 In addition, patency 
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Table I. Demographic characteristics and risk factors in directional atherectomy and BA groups 
Treatment group 
Variable No. with AT  (%) No. with BA (%) 
Sex 
Male 28 (74) 27 (77) 
Female 10 (26) 8 (23) 
Presenting symptoms 
Mild to moderate claudication 26 (68) 27 (77) 
Severe claudication 12 (32) 8 (23) 
Associated iseases and risk factors 
Diabetes mellitus 4 (10) 3 (9) 
Hypertension 8 (21) 4 (11) 
History of smoking 19 (50) 20 (57) 
Hyperlipidemia 11 (29) 8 (23) 
Coronary artery disease 15 (39) 15 (43) 
AT, Directional atherectomy. 
rates were determined by the life-table method 
restenosis or by occlusion being the endpoint. Only 
the primary patency rate was considered; the success 
ofreinterventions was no part of this analysis. One of 
the considerations in this regard was that other 
endovascular techniques than the treatment of ran- 
domization were to be allowed at reintervention, 
precluding any additional meaningful comparisons 
between the two treatment groups. Results at 
follow-up in the treatment groups were primarily 
compared according to the "intention-to-treat" prin- 
ciple, that is, early technical failures and attempted 
but abandoned procedures were considered end- 
points of patency, and patients with crossover 
treatments remained assigned to the treatment group 
of randomization. Deterioration of the clinical and 
hemodynamic status during follow-up was a second- 
ary endpoint studied by life-table analysis. Group 
comparisons for statistical differences in arterial 
patency and clinical success were performed with use 
of the log rank test. The Fisher exact est was used for 
comparison of discrete data in different groups, and 
for comparison of continuous variables the Mann- 
Whitney test was performed. Univariate comparison 
of patency rates in the total patient material was 
performed for multiple clinical and anatomic baseline 
factors. Nine variables were selected because of 
significant group differences at univariate compari- 
son or because of clinical relevance. These variables 
were sex, history of tobacco use, diabetes, preproce- 
dural ength of the index lesion, internal diameter of 
a normal SFA segment at color-flow duplex exami- 
nation, anatomic level of femoropopliteal disease 
(segment), degree of residual stenosis at the site of the 
reference l sion, number of lesions per limb treated, 
and the treatment group (atherectomy or BA). All 
nine factors were subjected to a multivariate analysis 
with a Cox proportional hazard model to examine 
independent associations) 2 With this model it was 
also investigated whether the ratio of failure rates of 
both treatments depended on baseline characteristics, 
that is, length of the lesion. The limit of statistical 
significance was set arp = 0.05 (two-sided). 
RESULTS 
Variables and procedural outcome 
Randomization produced two groups of patients 
that were comparable for most risk factors for 
peripheral arterial occlusive disease, the level and 
characteristics of lesions (Tables I and II). Thirty- 
eight patients underwent a herectomy and 35 under- 
went BA. The median duration of follow-up until 
death, reintervention, restenosis, or occlusion as 
indicated by color-flow duplex scanning or the last 
visit to the outpatient clinic was 13 months (range 0 
to 34) in patients treated with atherectomy and 13 
months (range 1 to 39) in patients treated with BA. 
The mean age was 64 years (range 49 to 77) in 
patients treated with atherectomy and 64 years 
(range 46 to 80) in the BA group. It should be noted 
that the patients in this study comprised a primarily 
favorable group, with only intermittent claudication 
and with lesions less than 5 cm in length. 
The procedural aspects and complications were 
comparable in the two treatment groups (Table IiI). 
The procedure was performed in 18 of the patients in 
the operating room and in all others in the angiog- 
raphy suite. Adjunct patch plasty of the common 
femoral artery and the deep femoral artery was 
required in five patients. The other indications for 
open endovascular p ocedures were scarred or obese 
groins and failure to obtain antegrade cannulation of 
the femoral artery. Four (5%) patients had a cross- 
over from the randomized technique to the opposite 
treatment. Acute thrombosis of the treated arterial 
segment during the procedure was encountered in 
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Table II. Characteristics of treated lesions and arteriographic aspects in AT and BA groups 
Treatment group 
Variable No. with AT (%) No. with BA (%) 
Localization of index lesion 
Proximal SFA ($1-$2) ~ 4 (10) 3 (9) 
Distal SFA ($3-$4) 31 (82) 27 (77) 
Popliteal (P1-P2) 3 (8) 5 (14) 
Degree of stenosis 
50%-69% 6 (16) 4 (11) 
70%-99% 31 (81) 29 (83) 
Occlusion 1 (3) 2 (6) 
Length of stenosis 
0-1.9 cm 26 (68) 25 (71) 
2-5 cm 12 (32) 10 (29) 
Eccentricity of stenosis 
None - mild 17 (45) 21 (60) 
Moderate- severe 20 (52) 12 (34) 
Occlusion 1 (3) 2 (6) 
Coexisting stenoses treated 13 (34) 10 (29) 
Crural runoff 
2-3 vessels 35 (92) 31 (89) 
0-1 vessels 3 (8) 4 (I1) 
AT, Directional atherectomy. 
Localization of lesions was according to an arbitrary classification the superficial femoral artery. SFA being subdivided into four segments 
(Sl-S4), the above-knee popliteat (P,) and the below-knee popliteal artery (P2). 
Table III. Procedural aspects and technical results in directional atherectomy and BA groups 
Treatment group 
Variable No. with AT (%) No. with BA (%) 
Place 
Angiography suite 27 (71) 
Operating room 11 (29) 
Adjunct operative procedures 4 (18) 
Use of opposite technique 3 (8) 
Complications 
Small dissection 1 (3) 
Large dissection 1 (3) 
Failure to pass guidewire 1 (3) 
Thrombosis/embolization ~ 1 (3) 
Significant hematoma 
Residual stenosis 
0%-29% 33 (87) 
~30% 5 (13) 
28 (80) 
7 (20) 
1 (3) 
1 (3) 
5 (14) 
32 
3 
(91) 
(9) 
AT, Directional atherectomy. 
~Thrombosis of treated segment symptomless resolved by local streptokinase application. 
one case, which was successfully treated with strep- 
tokinase. There were two technical failures: in one 
patient reated with atherectomy it was not possible 
to pass the guide wire through the diseased segment, 
whereupon the procedure was abandoned. In the 
second patient he atherectomy procedure was com- 
plicated by a large dissection with occlusion of the 
SFA after 3 months. In addition to the patients with 
technical failure, there was one more patient with a 
failure in the first month. In this patient, after an 
apparently successful procedure, the SFA occluded 
after 3 weeks. Residual stenoses of 30% or greater 
DR were seen in five patients treated with atherec- 
tomy and three treated with BA. However, in none 
of these cases the residual stenosis was greater than 
50% DR. Immediate operative intervention was not 
required in any patient. 
Clinical: and hemodynamic results at early and 
late follow-up 
No differences were found between the 
study groups in clinical/hemodynamic improvement 
within the first month, with increase of at least + 1 in 
34 (89%) patients treated with atherectomy and 34 
(97%) patients treated with BA. ABI levels during 
this period were similar as well, 0.92 +_ 0.14 in 
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Fig. 1. Cumulative-frequency distribution curves l°,u show percentage ofpatients with given 
PSV ratios at 3 months (Post-Atherect., Post-Balloon) and at time of highest observed PSV ratio 
during late follow-up (Fu-Atherect., Fu-Balloon). Value on ordinate represents percent of 
patients with PSV ratios greater than corresponding value at abscissa. Starting at normal level 
of approximately 1.0, I00% of patients have greater PSV ratios. Three-month curves nearly 
superimpose r flecting similar distribution of luminal dimensions among two treatment groups. 
At late follow-up, curve for atherectomy lies to right of curve for balloon angioplasty, reflecting 
increased tendency to restenosis n patients with AT. Percentage of patients with PSV ratio of 
2.5 or greater is 58% in patients with AT and 34% in patients with BA (dotted line). PSV ratio 
of three patients with AT and complete occlusions (two with technical failure and one with 
occlusion after 3 weeks) are not considered. Mean values and standard eviations of PSV ratios 
are indicated for four series of observations. 
patients treated with atherectomy and 0.89 _+ 0.16 
in the BA group. Of note, ABI were normalized 
( > 0.90) in only 42 (58%) patients. 
Follow-up ended because of death in three and 
because of surgical intervention for severe claudica- 
don or conversion to the stage of critical ischemia in 
three patients. Nineteen patients had repeat endovas- 
cular treatment, and two of the patients were lost to 
follow-up. When analyzed by life-table analysis, the 
cumulative rate of maintained improvement on the 
scale of clinical/hemodynamic results after 2 years of 
at least + 1 category was 66% (SE 7%) in all patients, 
52% (SE 9%) in the group treated with atherectomy, 
and 87% (SE 8%) in the group treated with BA 
(p = 0.06). This difference was not statistically sig- 
nificant. However, if the more stringent criterion of 
at least a +2 clinical/hemodynamic improvement 
was chosen, aless favorable result was observed in the 
atherectomy category, with a 2-year cumulative im- 
provement of only 38% (SE 11%) compared 
with 69% (SE 9%) in patients treated with BA 
(p = 0.04). This observation was supported by the 
finding of a mean ABI value at late follow-up of 
0.81 -4- 0.19 in patients treated with atherectomy 
and 0.88 -4- 0.16 in patients treated with BA. 
Color-flow duplex scanning follow-up 
The average number of duplex examinations 
performed until an endpoint was reached (PSV ratio 
> 2.5, occlusion, or end of follow-up) was 3.3 per 
patient (range 1 to 8). The cumulative frequency 
distribution of observed PSV ratios showed that, at 
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Table IV. Life-table analysis of primary patency rates of femoropopliteal arteries in directional 
atherectomy and BA groups 
Instal  No, at Failedfemoropop~teal No. In~rvalpaten~ Cumulativepa~n~ SE 
Treatment (mo~ ~sk a~e~es wi~drawn ra~ (%) ra~ (%) (%) 
AT 0-1 38 3 0 92 92 4 
1-3 35 0 0 100 92 4 
3-6 35 4 0 89 82 6 
6-9 31 8 0 74 61 8 
9-12 23 8 1 64 39 8 
12-15 14 0 2 100 39 8 
15-18 12 0 2 100 39 8 
18-21 10 0 2 100 39 8 
21-24 8 1 1 87 34 8 
24-30 6 1 1 82 28 9 
BA 0-1 35 0 0 100 100 0 
1-3 35 0 1 100 100 0 
3-6 34 5 2 85 85 6 
6-9 27 3 5 88 74 8 
9-12 19 2 2 89 66 9 
12-15 15 1 1 93 62 9 
15-18 13 0 1 100 62 9 
18-21 12 1 2 91 56 10 
21-24 9 0 3 100 56 10 
24-30 6 0 4 100 56 10 
AT, Directional atherectomy. 
Cumulative patency rates apply to the ends of intervals. 
first examination at3 months, the distribution of the 
atherectomy- and BA-treated patients is very similar 
(Fig. 1). However, when at late follow-up the PSV 
ratios reached their maximum values, these were 
higher in the atherectomy group, indicating a greater 
frequency of restenosis. Overall 34 (47%) patients 
had development ofa PSV ratio of 2.5 or greater in 
an initially treated segment. This was in 22 patients 
in the atherectomy category after a mean follow-up 
period of 8.7 months (range 3 to 26) and in 12 
patients in the BA category after 7.6 months (range 
3 to 19). A significant decrease of the PSV ratio 
indicating regression of lesions was observed in only 
three patients. Only a few patients had progression to
total occlusion: three in the atherectomy group and 
none in the BA group. Stenosis development outside 
the treated arterial segments was observed in 20 
(27%) patients, of whom four had two or more new 
lesions. New lesion development influenced the 
overall results minimally because only five patients 
had significant new disease without a recurrent 
stenosis at the treatment site. 
The cumulative 2-year patency rate, determined 
by restenosis or occlusion, in the overall group 
(intention-to-treat) was 44% (SE 9%) for all pa- 
tients, 34% (SE 8%) in the atherectomy group, and 
56% (SE 10%) in patients randomized to BA, a 
difference that just did not reach statistical signifi- 
cance (Fig. 2, Table IV). If the two technical failures 
were excluded from the life-table analysis, the 2-year 
patency rate was 36% (SE 11%) on patients treated 
with atherectomy and 56% (SE 10%) on patients 
treated with BA (p = 0.11). With multivariate 
analysis it appeared that of all clinical, arteriographic, 
and color-flow duplex scanning factors tudied, the 
diameter of the lesion and the combined variable 
consisting of lesion length and atherectomy treat- 
ment represented the most important factors related 
to failure of the procedure. In this study the length of 
the stenosis was dichotomized into a length less than 
2 cm and 2 cm or greater. Allowing for these factors 
none of the other evaluated characteristics were of 
additional prognostic value. Table V presents the 
relative risks of failure according to treatment, length 
of lesion, and diameter of the undiseased SFA. BA is 
associated with a significantly better patency rate than 
atherectomy for patients with a lesion length of 2 cm 
or greater (p = 0.007), although there is no apparent 
difference in patency rates between the treatments in 
patients with a lesion length less than 2 cm. Also the 
length of the lesion seems to be an important 
predicting factor of outcome only in patients treated 
by atherectomy. A further finding was that, with 
increasing diameter of undiseased SFA, the patency 
rate improved, irrespective of applied treatment. 
Reanalyzing the data with exclusion of the two 
patients with early technical failure did not affect he 
conclusions (Table V). 
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Fig. 2. Cumulative primary patency rates (Kaplan-Meier curves) in patients who underwent 
directional atherectomy and in patients with balloon angioplasty. Numbers represent patients 
at risk at indicated time points. 
Table V. Results of multivariate analysis of grouped variables influencing failure of procedure in 
the total patient group 
95% confidence limits 
Grouped variables Relative risk of failure relative risk p Value 
Group 1: lesions _> 2 cm + AT 
Group 2: lesions >2 cm + BA 
Group 3: lesions <2 cm + AT 
Group 4: lesions < 2 cm + BA 
Diameter of undiseased SFA segment 
1 (1 )*  - - 
0 .15  (0.18)1- 0.04-0.59 0.007 (0.016) 
0.21 (0.24)t 0.09-0.49 0.001 (0.003) 
0.20 (0.23)t 0.08-0.51 0.001 (0.005) 
0.51 (0.50)$ 0.33-0.79 0.003 (0.004) 
AT, Directional atherectomy. 
*Reference group. 
tNo significant difference amongst these three groups (p > 0.80). 
SRelative to arteries with 1 mm smaller diameter. 
Data between parentheses represent outcomes of analysis when patients with technical failure of the procedure are excluded. 
Fig. 3 (Table VI) shows the patency rates for the 
four groups according to the combination of length 
and treatment. Patients treated with atherectomy and 
with a lesion length of 2 cm or greater have a 
12-month patency rate as low as 14% (SE 11%). The 
three other groups all have better patency curves, 
which do not significantly differ from each other. The 
i2-month patency rate for the latter three groups 
combined was 62% (SE 7%). 
DISCUSSION 
Directional atherectomy was developed by Simp- 
son et al.t3 in I986, and the method was approved by 
the Food and Drug Administration for use in periph- 
eral arteries) 4 This device has been successfully 
used to open both stenotic and occluded vessels, 
with excellent early success and low complication 
rates. 1,4,s,tS,16 The procedural outcome in this study 
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Fig. 3. Cumulative primary patency rates in patients with directional atherectomy (AT) and 
balloon angioplasty (BA) with lesions of 2 cm or greater length and with smaller lesions. AT 
for lesions > 2 cm has a significantly ower patency rate. Numbers represent patients at risk at 
indicated time points. 
confirms these favorable aspects because only five 
(13%) of patients treated with atherectomy had a 
residual stenosis of 30% to 50% DR and only two 
(5%) had a technical failure. In addition, one patient 
had thrombosis of his treated segment, which was 
resolved by local thrombolysis. This low complica- 
tion rate carl perhaps in part be explained by our 
precaution of performing 29% of atherectomy proce- 
dures in the operating room via a cutdown approach. 
Proximal SFA lesions and scarred and obese groins 
may increase the risk of complications, and these situ- 
ations can be dealt with more easily by an open ap- 
proach? 7 In addition we found it advantageous to
perform in selected patients a patch plasty of the 
common femoral or deep femoral artery. Some au- 
thors have warned that the atherectomy device with 
its relatively large diameter required special familiar- 
ity with the system to avoid complications. ~8The 
material presented in our study does not contain a 
learning curve because, after atherectomy was intro- 
duced to our staff by one of the American initiators 
(Schwarten et al.1), it was practiced for several 
months before the study commenced. 
The best long-term results of endovascular p o- 
cedures in femoropopliteal occlusive disease are 
obtained in patients with intermittent claudication, 
with stenotic rather than occlusive lesions and with a 
good runoff. Indeed, most patients with these 
favorable conditions will not be considered candi- 
dates for reconstructive surgery. However, even in 
this ideal subset, a 3-year patency rate of BA was 
reported as 62% by Johnston et aL 19 Also Adar et al. 2° 
in a review of several published series tbund in 
patients with intermittent claudication a 62% 3-year 
patency rate. The 2-year patency rate obtained in our 
patients after BA of 56% is in agreement with this 
previous experience. 
Recurrent disease has to be discriminated from 
residual lesions, as well as from new disease at 
untreated segments. In this study no residual stenoses 
of greater than 50% DR were observed at completion 
arteriography, and therefore we assumed the inci- 
dence of residual esions after treatment quite low. 
New disease was identified in 27% of the patients. 
However, in only 7% there were no simultaneous 
restenoses. These findings confirm previous reports 
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Table VI. Life-table analysis of primary patency rates of femoropopliteal arteries in directional 
atherectomy and BA groups according to length of the treated lesion 
Failed Interval Cumulative 
Interval No. at femoropopliteal No. patency rate patency rate SE 
Treatment (too.) risk arteries withdrawn (%) (%) (%) 
AT + ksion <2 cm 0-1 26 0 0 100 100 0 
1-3 26 0 0 100 100 0 
3-6 26 1 0 96 96 4 
6-9 25 6 0 76 73 9 
9-12 19 6 0 68 50 10 
12-15 13 0 2 100 50 10 
AT + lesion ~2 cm 0-1 12 3 0 75 75 12 
1-3 9 0 0 100 75 12 
3-6 9 3 0 67 50 14 
6-9 6 2 0 67 33 14 
9-12 4 2 1 43 14 11 
12-15 1 0 0 100 14 10 
BA+ ~sion <2 cm 0-1 25 0 0 100 100 0 
1-3 25 0 0 100 100 0 
3-6 25 3 2 88 88 7 
6-9 20 2 4 89 78 9 
9-12 14 2 2 85 66 11 
12-15 10 1 0 90 59 12 
BA+ ~sion ~2 cm 0-1 10 0 0 100 100 0 
1-3 10 0 1 100 100 0 
3-6 9 2 0 78 78 14 
6-9 7 1 1 85 66 16 
9-12 5 0 0 100 66 16 
12-15 5 0 1 100 66 16 
that the late results ofendovascular procedures in the 
vast majority are determined by true recurrent 
disease. 21,22 Although it was our primary objective to 
compare the late patency rates of two treatments this 
study has focused on recurrent obstructions. 
Restenotic lesions of BA invariably consist of 
myointimal hyperplasia. 3'23'24 The primary mecha- 
nism of luminal enlargement by BA of femoral 
arteries is overstretching of the wall, and this injury 
may have a direct association with restenosis forma- 
tion. Overstretching is often accompanied bydissec- 
tion, plaque rupture, and occasionally by rupture of 
the internal laminaY 5 Simpson et al.13 intended their 
directional atherectomy catheter to prevent dissec- 
tions and irregularities to leave a smooth surface of 
the remaining vessel wall, with the expectation to 
reduce the restenosis rate. Early reports seemed to 
confirm these xpectations with 1- to 2-year patency 
rates of 72% to  88%.  5'16'26'27 Because of these 
promising results, the documented low complication 
rate, and the interesting concept, this randomized 
prospective study was conducted to test the hy- 
pothesis that atherectomy would provide better 
results in patients with intermittent clandication, 
stenotic lesions, or very short occlusions and a good 
runoff. The study design provided for the intention- 
to-treat principle, standard criteria for improve- 
ment by the use of the Society for Vascular 
Surgery/International Society for Cardiovascular 
Surgery clinical and hemodynamic scale and a color- 
flow duplex scanning follow-up protocol for objec- 
tive documentation f patency with significant reste- 
nosis or occlusion as a primary endpoint. Evaluation 
of clinical and hemodynamic mprovement alone 
does not suffice for a controlled comparative study, 
because it incompletely reflects the anatomic events. 
In this study we found a 66% overall 2-year success 
rate in clinical and hemodynamic classification as 
opposed to a 44% anatomic patency rate. This 
discrepancy has been explained by the fallibility of 
symptoms as a parameter for follow-up. Collateral 
vessel development may abolish the return of symp- 
toms in cases of recurrent disease. 11 Moreover, the 
resting ABI has not always been found to reflect he 
presence of stenoses after endovascnlar proce- 
dures. 28,29 
Duplex examination and, more recently, color- 
flow duplex imaging are generally accepted as highly 
accurate tests for the diagnosis of obstructive l sions 
in the femoropopliteal pathway and for grading the 
severity of stenoses? °'31 They are ideally suited for 
comparative r stenosis studies like this one because 
serial use allows accurate stimation of the time the 
occlusive vents occur. 32'33 Differentiating recurrent 
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lesions in the treated segments from newly develop- 
ing obstructions could be performed practically by 
arbitrary division of the femoropopliteal system into 
six segments at arteriography and by use of a ruler at 
color-flow duplex examination. A PSV ratio of 2.5 or 
greater was the adopted criterion for restenosis 
according to the recommendations of Legemate t 
al.31 These authors established this ratio to provide 
the best discrimination of lesions of 50% or greater 
diameter reduction, a finding that could be confirmed 
in our own vascular laboratory. 
This trial was contemplated-with a null hypothesis 
of similar results observed in the experimental group 
(atherectomy) and the control group (BA). The 
condition to reject the null hypothesis was a better 
outcome of atherectomy in a sufficiently large num- 
ber of patients. This condition was not satisfied 
because no significant advantage of the use of 
atherectomy could be demonstrated in a study 
population of 73 patients. At the conclusion of our 
study, the 2-year patency rate was 34% in patients 
undergoing atherectomy and 56% in patients treated 
with BA, with a strong trend (p = 0.07) of a 
difference in the opposite direction. 
Although our patency rate in patients treated with 
atherectomy is considerably ower than patency rates 
over 70% reported by others ,  5'16'26"27 it is in agree- 
ment with a lesion recurrence of 53% after 6 months, 
as was recently reported by Dorros et al. 34 These 
authors tudied late results of treated iliac and femo- 
ropopliteal arteries in 115 patients, with arterio- 
graphic follow-up in most. Nearly 85% of the recur- 
rent lesions were in the infrainguinal arteries. The 
difference with earlier studies may be explained by 
their use of arteriographic rather than clinical and 
hemodynamic criteria for success. Also Katzen et al. 6 
found a disappointing patency rate of 37% after 2 
years, and they concluded that this was lower than 
what would be expected in balloon angioplasty. Infe- 
rior results of atherectomy are also suggested by our 
observations ofa lower rate of clinical/hemodynamic 
success. This was 52% in patients treated with 
atherectomy compared with 87% in patients treated 
with BA after 2 years. If the more stringent criterion 
for improvement of + 2 was used, the difference was 
even greater and reached statistical significance. 
Restenosis after atherectomy has been explained 
in the literature in various ways. 18,35 Insufficient 
tissue removal, luminal enlargement partially caused 
by the distending effect of the low pressure balloon, 
and a higher ate ofmyointimal hyperplasia from the 
greater arterial trauma caused by the device all have 
been proposed as cause of luminal loss, be it at 
different follow-up periods. PSV ratio representation 
in cumulative frequency distribution curves allowed 
the restenosis process to be studied more closely. In 
these graphs PSV ratios were viewed as a continuous 
variable. Observations are represented of duplex 
examination at 3 months and at the time that the 
highest PSV ratio was observed. This approach was 
used to analyze whether the restenosis parameter 
differs between the two treatment groups at first 
examination and at a later time during follow-up. The 
ability of a relatively new device, such as the 
atherotome, to influence the restenosis pattern de- 
pends on initial lumen gain at the procedure and on 
the process of myointimal hyperplasia causing reste- 
nosis. The net result depends on which effect is 
strongest. This approach as been used previously to 
compare new interventional methods in coronary 
artery disease, l°'n It appears that, at the first exami- 
nation, there is little difference between atherectomy- 
and BA-treated patients, and the overall incidence of 
PSV ratio greater than 2.5 is less than 10% (Fig. 1). 
However, at the time of the highest measured PSV 
ratio, the difference is appreciable. From this obser- 
vation one may conclude that a lack of initial gain, 
corresponding to residual disease, is relatively unim- 
portant for the difference in the late stenosis rate. The 
time period of approximately 8 months between the 
procedure and the increase of the PSV ratio suggests 
that increased myointimal hyperplasia in patients 
treated with atherectomy is the primary responsible 
factor for decline of patency. Observations that 
myointimal hyperplasia restenosis after atherectomy 
is histologically identical to that occurring after BA 
confirm the concept of a common healing response of 
the vessel wall after different endovascular t eat- 
ments. 23'3s The observed ifference in PSV ratio that 
occurred during follow-up between the two treat- 
ment modalities (Fig. 1) may be explained by their 
different effects on smooth muscle cells of the media 
layer, mechanical stretching by BA or both. 
At risk factor analysis with a multivariate Cox 
model, only the length of the index lesion combined 
with the type of treatment and the internal diameter 
of the SFA at an undiseased segment explained the 
greatest proportion of a difference in treatment 
outcome. All other explanatory variables did not 
correlate with a higher rate of late failure. Several 
previous studies on BA have also found stenosis 
length a significant risk factor with lesions longer 
than 2 cm being associated with an increased 
likelihood of restenosis.7,36,37 In arecent proposal for 
reporting standards for lower extremity arterial 
endovascular procedures by Aim et al., 38 stenoses 
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with a length less than 2 cm are designated A lesions, 
whereas B and C indicate longer and more complex 
lesions presumably associated with a less favorable 
treatment result. Our observation confirms the prac- 
tical value of this classification. The importance of the 
size of the normal SFA can easily be seen because an 
initially adequate postprocedure luminal diameter 
will sooner be negated by myointimal hyperplasia n
a smaller artery. For the measurement of normal 
vessel dimensions, duplex scanning appears to be a 
practical and accurate method. The significance of the 
diameter of the normal SFA has to our lmowledge 
not been examined before as a variable influencing 
restenosis tendency. The reason probably is that the 
use of duplex scanning to study the outcome of 
endovascular procedures i only recently practiced. 
Among the other factors that previously have 
been correlated with a lower frequency of restenosis 
after atherectomy are an eccentric appearance of the 
initial lesion, and many authors now consider this 
type of stenosis particularly suitable for treatment 
with atherectomy, s's9,4° Von P61nitz et al. s reported 
angiographic restenosis n 24% of concentric lesions 
and 11% of eccentric lesions. In this study eccentric- 
ity as observed in the univariate risk factor analysis 
was not associated with a lower frequency of reste- 
nosis. Recurrent lesions were seen in 20 of 32 
patients with moderate to severe eccentric stenoses 
and in 17 of 3 8 concentric lesions, which prevalences 
are statistically comparable. Residual stenosis of 30% 
or greater on the completion arteriogram has been 
associated with recurrence of disease in atherectomy 
as well as in BA. 4'32 Because only five of our patients 
treated with atherectomy had residual stenoses of 
30% or greater, we could not correlate this factor 
with the tendency to restenosis. The importance of a 
radical atherectomy to achieve durable success has 
also been emphasized, and some investigators expect 
the extensive removal of atherosclerotic ssue to limit 
the hyperplastic response to injnry, a9'41 However, in 
coronary arteries radical atherectomy with exposure 
of deep wall components did not result in a significant 
decrease of the myointimal hyperplastic process. The 
only explanation for a slightly better lumen 6 months 
after the intervention was an initially larger luminal 
diameter in atherectomy compared with BA. m Also 
in peripheral arteries the increased luminal cross- 
sectional area created by deep atherectomy rather 
than extensive xposure of arterial media is suggested 
to result in a delay of timing of clinical restenosis, as
At present there is little evidence that a radical 
atherectomy will provide better esults than a mod- 
erately extensive procedure. 
With the outcome of this study in mind, what 
could one still consider a specific indication for 
directional atherectomy? Obtaining histology speci- 
mens for research purposes is a definite area for its 
use. Study of retrieved material demonstrated no 
histologic differences between restenoses occurring 
after BA and those seen after atherectomy. 23,24 Most 
other specific indications are a matter of personal 
preference. Eccentric, bulky, and calcified stenoses 
and lesions with high risk of embolization have been 
suggested to be particularly suitable for atherectomy 
treatment. 4° We agree with this view that atherec- 
tomy is to be used if a lesion does not appear to 
respond on simple BA. Restenotic lesions may have 
different responses on treatment han de novo 
atherosclerotic obstructions, and perhaps this area is 
worthwhile to be examined prospectively. Finally 
combined use of atherectomy and BA may have 
attractive aspects to some interventionalists. In fact, 
some of the reports on the use of atherectomy 
comprised a portion of patients treated by combined 
techniques, i6 27 We do not believe that combined use 
with BA will make atherectomy generally more 
applicable because it has been demonstrated that 
removal of atheromatous plaque is not the sole 
mechanism whereby luminal enlargement is ob- 
tained. Retrieved atheroma ccounted for only 30% 
of increased luminal volume, and tissue weight did 
not correlate with the increased luminal vo lume.  2'42 
Low-pressure balloon dilation was believed to con- 
tribute to luminal enlargement, 2'18 and this leaves one 
to wonder how important removing obstructive 
material is for durable patency. 
In conclusion, contrary to previous reports in 
which atherectomy was accepted as a valuable xpan- 
sion of the endovascular interventional rmamen- 
tarium 16,26,27 we do not believe that a widespread use 
of atherectomy for treatment of femoropopliteal 
obstructive disease isjustified. In the overall group no 
advantage of atherectomy could be demonstrated. In 
a subgroup analysis, atherectomy for lesions of 2 cm 
or greater was associated with a 12-month patency of 
14%, ~ which was significantly worse than similar 
lesions treated by BA. Only in patients with lesions 
less than 2 cm the patency rate was comparable tothat 
obtained by BA. 
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DISCUSSION 
Dr. Rodney A. White (Torrance, Calif.). The authors 
are commended for addressing a topic of interest regarding 
contemporary endovascular therapy of peripheral vascular 
lesions with well-chosen, randomized criterion and for 
reporting data with SVS/ISCVS guidelines. The use of 
duplex scanning to document long-term patency is par- 
ticularly relevant, and I agree entirely with their comment 
that "Evaluation of clinical and hemodynamic mprove- 
ment alone does not suffice for a controlled comparative 
study." The finding of a 66% overall 2-year success rate 
with clinical and hemodynamic classification compared 
with a 44% anatomic patency rate confirmed by duplex 
scanning substantiates this point. I also concur with their 
observations that arteriography does not accurately indi- 
cate the amount of retained plaque in the vessel, and that 
only intravascular ultrasonography (IVUS) has the poten- 
tial to maximize lumen enlargement by endovascular 
procedures. The observation that arteriography suggested 
significant stenoses after BA in only two of 14 patients 
evaluated, whereas IVUS demonstrated residual esions 
and unsuspected abnormalities in 12 patients ubstantiates 
this position. 
I have some concerns regarding the choice of patients 
for the interventions and regarding the comparability ofthe 
randomized groups because all patients did not receive 
interventions based on the same criterion. As the authors 
have suggested, short lesions (-< 2 cm) respond best to 
endovascular interventions. The fact that nearly 50% of the 
patients in their study had lesions longer than 2 cm or had 
diffuse disease limits the ability to interpret the efficacy of 
individual interventions on isolated short lesions. The 
significance of the length of disease is exemplified by the 
fact that, of all patients treated, only 59% had normalized 
ABIs after the intervention. In addition, treatment of 
second and third obstructive l sions in the same vessel with 
use of the same technique also complicates interpretation. 
How do you explain the discrepancy in the patency rate 
you observed for short lesions being treated by atherectomy 
with the 1- to 2-year patency rates of 72% to 88% that have 
been reported in the publications you referred to? 
There is no report of histology from the specimens that 
were removed in this study. Histologic onfirmation of the 
type of tissue removed is an important factor because 
previous reports suggest hat atherectomy to the level of 
media of the artery enhances lesions recurrence. 
Dr. Jacob Buth. If we have given the impression that 
we were treating complicated cases with atherectomy we 
did not make that point clear. The study group consisted of 
only one third of all our femoropopliteal endovascular 
treatments, and, indeed, it was a very stratified material; 
only lesions shorter than 5 cm for stenosis and shorter than 
2 cm for occlusion were included. In addition, this series 
consisted only of patients with intermittent claudication. 
As a result, this was a category that was otherwise 
considered for conservative therapy but certainly was not 
the difficult category for endovascular treatment. 
One of your comments was about not normalizing the 
ABI. It has been described several times in the literature 
that even after successful endovascular treatment, ABI does 
not completely normalize. This has been ascribed to minor 
diffuse disease elsewhere that was not picked up by 
preoperative angiography. 
One of the remarks was that IVUS was not used in the 
BA group, and only in 14 patients treated with atherec- 
tomy. In the 3 years of this prospective study, the IVUS 
technique was developed, and it was not available in our 
hospital at the beginning of this series. Nevertheless, it was 
a development that could not be denied as being important, 
especially for the atherectomy treatment. In our view, it was 
not as important in BA because of the difference in 
mechanisms of action between the two treatment modali- 
ties. BA works in a circumferential way, and identification 
of a suboptimal result would only have resulted in 
additional attempts to dilate normal arterial wall, which is 
the primary mechanism of BA. In contrast, atherectomy is 
directional, and IVUS is ideally suited to be used with this 
technique. You can localize any point of the circumference 
where the remaining atheroma issituated and try to remove 
it completely. This was done in 12 of the 14 patients. 
Your other questions regarded iscrepancies of our 
results with the literature. Previous publications often used 
short follow-up times. But ours is not the only report hat 
has documented poor results of directional atherectomy. 
Recent reports by Dorros (Cathet Cardiovasc Diagn 
1991;22:79-84) and Katzen (J Vase Int Radiol 1992;3: 
38-9) were in agreement with our findings. 
You made a remark that there is no histologic study 
done in our study. Histology is important, but it was not 
a part of this study. It may have good promise for the 
future; it's an interesting feature, especially from the 
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research point of view. The studies you are alluding to were 
coronary artery studies where an advantage was shown of 
radical atherectomy with the media removed. The cause of 
the better esults in this radical atherectomy probably was 
the greater initial luminal gain, producing a larger lumen 
compared with the less radical atherectomy. 
The important message of our study is that in a 
randomized trial, it was demonstrated that atherectomy 
does not have any advantage for routine use, even for 
modest femoropopliteal lesions. 
Dr. Samuel S. Ahn (Los Angeles, Calif.). This study 
is important in putting peripheral atherectomy in its 
current form to rest. The results are virtually identical to 
our results with the Rotablator used to perform peripheral 
atherectomy, (J VASC SURG 1994;19:509-14). In that 
study, we also found a very dismal 20% patency rate at 2 
years. 
I think we were misled several years ago by several 
reports of a 70% to 80% success rate. What was not 
obvious in those reports was that there was only a 6-month 
follow-up. You showed that, at 6 months, the patency rate 
is indeed about 70%. The problem is that there is a big 
drop-off shortly thereafter. Perhaps these two studies with 
longer follow-up will put peripheral atherectomy to rest. 
Rodney White, at one time, made a point that perhaps 
we could get better results if we did a more complete 
atherectomy with the help of ultrasound guidance. You 
stated that it did not make a difference. However, there was 
some difference. It was 57% versus 71% patency in favor 
of the ultrasonography group. Although it was not 
statistically significant, your numbers were small and thus 
subject o a type II statistical error. Have you done any 
calculations to determine how many patients it would 
require to show a statistically significant difference? 
Dr. Buth. It's remarkable that rotational atherectomy 
provides approximately the same results as directional 
atherectomy. Maybe the mechanical action is the prime 
factor that gives rise to an increased intimal hyperplasia 
rate. 
With regard to your question about the difference be- 
tween the intravascular ultrasonography-monitored g oup 
and nonintravascular ultrasonography-monitored group, 
the figures that are given in the abstract are the actual 
figures of failures, caused by restenosis. Because restenosis 
and occlusion are time-dependent factors, it is more appro- 
priate to use life-table analysis here. When we used a life- 
table analysis, the 1-year patency rates were almost identi- 
cal, 42% and 43% in the two groups. It would require an 
extremely large group to demonstrate a significant differ- 
ence, which is highly unlikely to exist. 
Dr. George Andros (Burbank, Calif.). It seems to me 
that new devices get a foothold in clinical practice because 
they seem plausible. What could be more plausible than 
having a closed endarterectomy, which this technique 
seems to resemble? It has taken a prospective trial of this 
sort to show that what is plausible technology may not be 
valid. Your data analysis has shown this to my satisfaction. 
In particular your velocity ratio analysis is good. 
Several years ago Dr. Strandness pointed out to us that 
you could use a hot-tipped laser probe to make a guide hole 
for BA and that you never have to turn the probe on. Using 
that experience as a stimulus, we did an analogous 
procedure with the directional atherocath on three patients 
who had short eccentric stenotic lesions. We introduced the 
device and inflated the balloon to 2 arm but never activated 
the rotational cutting element. We found that intraproce- 
dure ankle-arm indexes nearly normalized without any 
atherectomy. These three patients had effective BA, and 
their arteries are still patent. I share this anecdote to raise 
a question about the mechanism of action of this device. 
How much of the effect do you think is the result of an 
elegant but expensive balloon dilation, and how much do 
you think is due to plaque removal? 
My second question relates to recurrent lesions. Do you 
have any data whether they are worse after atherectomy or
BA? 
Dr. Buth. You are touching on the working mecha- 
nism of directional atherectomy. It certainly is true that it 
is not only the atheroma removal that causes lumen 
enlargement, but also the distention of the low-pressure 
balloon used to engage the housing at the side of the 
atheroma. 
When you ask what would be the percentage oftumen 
enlargement caused by balloon dilation and by atheroma 
removal, I cannot give you an exact answer. Investigations 
on coronary atherectomy demonstrated that only 30% of 
its action is due to atheroma removal. That seems a rather 
low percentage, because we believe we can remove quite a 
bit more from the superficial femoral artery by with our 
larger device. 
